A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.57 USD -5.38% Market Closed
Market Cap: 416.1m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Capital Expenditures
-$229k
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Capital Expenditures
-$4.4B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Capital Expenditures
-$1.2B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Pfizer Inc
NYSE:PFE
Capital Expenditures
-$3.2B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Capital Expenditures
-$3.4B
CAGR 3-Years
10%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Capital Expenditures
-$8.3B
CAGR 3-Years
-53%
CAGR 5-Years
-38%
CAGR 10-Years
-18%

See Also

What is Aquestive Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-229k USD

Based on the financial report for Jun 30, 2024, Aquestive Therapeutics Inc's Capital Expenditures amounts to -229k USD.

What is Aquestive Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
31%

Over the last year, the Capital Expenditures growth was 91%. The average annual Capital Expenditures growth rates for Aquestive Therapeutics Inc have been 27% over the past three years , 31% over the past five years .

Back to Top